[go: up one dir, main page]

WO2014009970A3 - Linagliptin solid dispersion - Google Patents

Linagliptin solid dispersion Download PDF

Info

Publication number
WO2014009970A3
WO2014009970A3 PCT/IN2013/000417 IN2013000417W WO2014009970A3 WO 2014009970 A3 WO2014009970 A3 WO 2014009970A3 IN 2013000417 W IN2013000417 W IN 2013000417W WO 2014009970 A3 WO2014009970 A3 WO 2014009970A3
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
solid dispersion
preparation
pharmaceutically acceptable
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2013/000417
Other languages
French (fr)
Other versions
WO2014009970A2 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Kesireddy Subash Chander Reddy
Bandi Vamsi Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to US14/589,495 priority Critical patent/US9381199B2/en
Publication of WO2014009970A2 publication Critical patent/WO2014009970A2/en
Anticipated expiration legal-status Critical
Publication of WO2014009970A3 publication Critical patent/WO2014009970A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
PCT/IN2013/000417 2012-07-09 2013-07-08 Linagliptin solid dispersion Ceased WO2014009970A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/589,495 US9381199B2 (en) 2012-07-09 2013-07-08 Linagliptin solid dispersion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
INCH27802012 2012-07-09
ININ2780/CHE/2012 2012-07-09

Publications (2)

Publication Number Publication Date
WO2014009970A2 WO2014009970A2 (en) 2014-01-16
WO2014009970A3 true WO2014009970A3 (en) 2015-07-30

Family

ID=49916619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000417 Ceased WO2014009970A2 (en) 2012-07-09 2013-07-08 Linagliptin solid dispersion

Country Status (1)

Country Link
WO (1) WO2014009970A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381199B2 (en) 2012-07-09 2016-07-05 Hetero Research Foundation Linagliptin solid dispersion
US10253026B2 (en) * 2015-06-25 2019-04-09 Boenringer Ingelheim International GmbH Process for the preparation of (r)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1h-purine-2,6-dione
EP3452727B1 (en) * 2016-05-03 2021-09-29 Carrier Corporation Inlet for axial fan
CN112961155A (en) * 2021-03-16 2021-06-15 华北水利水电大学 Preparation method of linagliptin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20100209506A1 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20110263617A1 (en) * 2008-09-10 2011-10-27 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20120046224A1 (en) * 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20110263617A1 (en) * 2008-09-10 2011-10-27 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20100209506A1 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120046224A1 (en) * 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome

Also Published As

Publication number Publication date
WO2014009970A2 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
IL279304A (en) Cytotoxic benzodiazepine derivatives, compositions comprising the same and uses thereof
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL239639A0 (en) Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
WO2011130615A3 (en) Preparation of lacosamide
WO2013150495A3 (en) Preparation of ticagrelor
HUE037747T2 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
HK1206028A1 (en) Phenicol antibacterials
MX359288B (en) Ivabradine hydrochloride form iv.
IL214662A0 (en) Base, products containing the same, preparation methods and uses thereof
WO2013164839A8 (en) Amorphous form of apixaban, process of preparation and compositions thereof
IN2012DN02793A (en)
WO2012085927A3 (en) Tadalafil compositions
IL212942A (en) Rifamycin derivatives, process for their preparation, pharmaceutical compositions comprising the same and uses thereof
IL233055A0 (en) (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof
WO2014009970A3 (en) Linagliptin solid dispersion
IL225440A (en) Cyclohexane derivatives, compositions comprising the same and uses thereof
PH12013500210A1 (en) Highly crystalline valsartan
IN2012CH01309A (en)
WO2014105777A8 (en) Cobicostat dichlohydrate salt
WO2014115169A3 (en) Crizotinib solid dispersion
WO2014013511A3 (en) Rufinamide solid dispersion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816209

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14589495

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13816209

Country of ref document: EP

Kind code of ref document: A2